Global Bio-chem Technology Group Co. Ltd. (0809) AI Stock Analysis

• Market Cap: HK$846.20M
• Dividend Yield: N/A
• Average Volume (3M): 4.49M
• Price to Earnings (P/E): 1.1
• Beta (1Y): -0.32
• Revenue Growth: 42.14%
• EPS Growth: -81.25%
• Country: HK
• Employees: 1,567
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Packaged Foods
• EPS (TTM): -0.02
• Shares Outstanding: 16,832,771,000
• 10 Day Avg. Volume: 10,283,400
• 30 Day Avg. Volume: 4,490,276
• PEG Ratio: -0.02
• Price to Book (P/B): -0.48
• Price to Sales (P/S): 0.47
• P/FCF Ratio: 12.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by the company's financial instability, characterized by negative equity and high leverage. Technical indicators provide a neutral outlook, while the low P/E ratio suggests potential undervaluation. The absence of earnings call data and corporate events limits further insights.

Global Bio-chem Technology Group Co. Ltd. Business Overview & Revenue Model

Company Description

Global Bio-chem Technology Group Company Limited, an investment holding company, manufactures and sells corn refined products and corn-based biochemical products in the People's Republic of China, rest of Asia, the Americas, and internationally. It operates through four segments: Upstream Products, Amino Acids, Corn Sweeteners, and Polyol Chemicals. The company offers corn refined products, including corn oil, corn steep liquor, corn starch, waxy corn starch, corn gluten meal, feed pellets, and corn germ cake. It also provides downstream corn based biochemical products, such as amino acids comprising lysine, protein lysine, threonine, and glutamic acid; corn sweeteners, which include high fructose corn syrup, maltodextrin, high maltose syrup, maltose syrup, sorbitol, glucose, and crystallized glucose; modified starches; and chemicals comprising ethylene, propylene, and butylene glycols, as well as resins. In addition, the company offers anti-freeze products, hydrogen, and ammonia. Its products are used in various applications, such as feed production, food and beverage, cosmetics, textiles, pharmaceuticals, chemical industries, etc. The company was founded in 1994 and is headquartered in Hung Hom, Hong Kong.

How the Company Makes Money

Global Bio-chem Technology Group Co. Ltd. generates revenue primarily through the production and sale of its core bio-based products. The company operates an integrated business model that spans the entire value chain from raw material procurement to the final production of high-value products. Key revenue streams include the sale of amino acids, such as lysine and threonine, which are essential in animal nutrition, and corn sweeteners used in the food and beverage industry. Additionally, the company produces polyols, which find applications in the cosmetics and pharmaceuticals sectors. Strategic partnerships with agricultural suppliers and collaborations with industry leaders enhance the company's market presence and contribute to its financial performance.

Global Bio-chem Technology Group Co. Ltd. Financial Statement Overview

Summary

The company exhibits major financial instability with negative equity, high leverage, and inconsistent cash flows. Despite recent improvements in revenue and operating cash flow, the company remains at risk due to historical losses and financial distress.

Income Statement

The company shows significant volatility in revenue, with a recent increase from 2022 to 2023, but overall negative EBIT and net income suggest underlying profitability issues. The negative EBIT margin underscores operational challenges, while EBITDA margin turning positive in 2024 reflects some improvement in operating efficiency.

Balance Sheet

The company faces severe financial instability with negative stockholders' equity reflecting balance sheet insolvency, and a high debt-to-equity ratio indicating excessive leverage. The negative equity ratio further highlights financial distress, posing considerable risks.

Cash Flow

Cash flow from operations has improved from negative to positive in 2024, indicating better cash management. However, the free cash flow still faces challenges due to historical negative trends, and the operating cash flow to net income ratio is volatile, highlighting cash flow unpredictability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.29B	2.00B	1.37B	12.71M	746.55M	848.87M
Gross Profit	313.85M	218.68M	43.64M	-263.37M	48.35M	74.10M
EBITDA	104.98M	16.85M	4.69B	-469.06M	785.63M	-1.39B
Net Income	772.61M	769.60M	4.22B	-1.44B	-400.80M	-2.43B
Balance Sheet
Total Assets	4.69B	4.54B	5.21B	5.85B	6.48B	7.60B
Cash, Cash Equivalents and Short-Term Investments	221.55M	85.47M	315.41M	41.77M	109.13M	153.32M
Total Debt	3.60B	3.69B	5.45B	8.91B	8.44B	8.96B
Total Liabilities	6.89B	6.50B	9.25B	13.64B	13.18B	13.62B
Stockholders Equity	-2.21B	-1.95B	-4.04B	-7.54B	-6.52B	-5.86B
Cash Flow
Free Cash Flow	64.48M	76.04M	-94.24M	-94.19M	-501.02M	-43.02M
Operating Cash Flow	67.68M	76.04M	-50.46M	-88.01M	-475.21M	-26.19M
Investing Cash Flow	-3.74M	-535.00K	-14.37M	-413.00K	392.59M	120.09M
Financing Cash Flow	29.89M	-76.06M	112.62M	109.75M	-48.66M	-25.87M

Global Bio-chem Technology Group Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0809, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.09, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.75 is Neutral, neither overbought nor oversold. The STOCH value of 37.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0809.

Global Bio-chem Technology Group Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2317	77 Outperform	HK$1.02B	8.55	5.31%	10.12%	-1.19%	-9.05%
1767	68 Neutral	HK$290.00M	10.98	7.70%	0.79%	5.43%	-25.42%
3838	63 Neutral	HK$1.18B	2.60	11.75%	4.97%	-6.58%	16.23%
0829	59 Neutral	HK$936.84M	-39.73	1.16%	13.79%	-4.42%	-157.03%
0809	52 Neutral	HK$846.20M	1.09	―	―	42.14%	-81.25%
2147	51 Neutral	HK$41.44M	-0.55	-12.87%	―	32.15%	-171.32%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%

Global Bio-chem Technology Group Co. Ltd. Corporate Events

Global Bio-chem Technology Reports Increased Revenue but Sustains Losses in H1 2025

Global Bio-chem Technology Group Co. Ltd. reported its unaudited consolidated interim results for the six months ending June 30, 2025, showing a revenue increase to HK$1,185,983,000 from HK$898,541,000 in the same period of 2024. Despite the revenue growth, the company faced a total comprehensive loss of HK$251,895,000, attributed to high finance costs and other expenses, impacting its financial performance and indicating challenges in maintaining profitability.

Global Bio-chem Announces Extraordinary General Meeting for Strategic Approvals

Global Bio-chem Technology Group Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for September 18, 2025, in Hong Kong. The meeting aims to approve resolutions related to the company’s strategic plans, including the allotment and issuance of Consideration Shares under Specific Mandates. This move is expected to impact the company’s operational strategies and potentially influence its market positioning.

Global Bio-chem Announces Delay in Debt Restructuring Circular

Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The circular, initially expected by 22 August 2025, will now be dispatched by 5 September 2025, as additional time is needed to finalize certain information. This delay may impact stakeholders awaiting detailed information on the debt restructuring and share issuance.

Global Bio-chem Technology Schedules Board Meeting for Interim Results

Global Bio-chem Technology Group Co. Ltd. has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.

Global Bio-chem Secures EPC Contract for Boiler Refurbishment

Global Bio-chem Technology Group Co. Ltd. announced the successful closure of a public tender for an EPC Contract related to a Boiler Refurbishment Project. The contract, valued at a maximum of RMB129.1 million, was awarded to Northeast Electric and Liaoning Electric as joint bidders. This transaction is classified as a discloseable transaction under the Listing Rules due to its size, requiring notification and announcement. The project involves comprehensive engineering, procurement, and construction tasks, with incentives for early completion, potentially impacting the company’s operational efficiency and market positioning.

Global Bio-chem Technology Delays Circular Dispatch for Debt Restructuring

Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The delay is due to the need for additional time to prepare and finalize necessary information, with the new dispatch date set on or before August 22, 2025. This delay may impact the company’s operational timelines and stakeholder expectations, as the circular is crucial for informing shareholders about the upcoming Extraordinary General Meeting and related transactions.

Global Bio-chem Announces Debt Restructuring and Equity Re-acquisition

Global Bio-chem Technology Group Co. Ltd. has announced a Suppliers Debt Restructuring Arrangement involving the re-acquisition of equity interest in Century Dacheng. This arrangement includes a debt-to-equity conversion and an equity-swap, resulting in Century Dacheng becoming an indirect wholly-owned subsidiary of the company again. The restructuring will be settled through the issuance of Consideration Shares, which will significantly affect the company’s share capital. The completion of this arrangement is subject to approval at an Extraordinary General Meeting (EGM), where shareholders will vote on the re-acquisition and the issuance of the Consideration Shares.

Global Bio-chem Advances Debt Restructuring with Equity Swap and Supplier Settlements

Global Bio-chem Technology Group Co. Ltd. has announced the completion of a Debt-to-Equity-Swap Agreement, resulting in Suppliers PRC LLPs holding a 28.98% equity interest in Century Dacheng. The company is progressing with its Suppliers Debt Restructuring Arrangement, expected to conclude by the end of 2025, pending necessary approvals. Concurrently, the company has reached settlement agreements with 33 remaining suppliers involving a significant debt discount, resulting in a projected net gain of no less than HK$17.0 million. These strategic financial maneuvers are aimed at stabilizing the company’s financial position and enhancing its operational capabilities.